<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361529</url>
  </required_header>
  <id_info>
    <org_study_id>ACEA100108(FLP)</org_study_id>
    <nct_id>NCT01361529</nct_id>
  </id_info>
  <brief_title>Safety Study of FLP Injection to Treat Tumor Patients</brief_title>
  <official_title>Phase 1 Study of FLP Injection on Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acea Bio (Hangzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acea Bio (Hangzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the tolerance and maximum tolerated dose (MTD) for&#xD;
      FLP Injection with multiple dose in tumor patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the tolerance and MTD for FLP Injection with multiple dose in tumor patients.&#xD;
&#xD;
      To test clinical pharmacokinetics (PK) and PK parameter&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse effect assessment</measure>
    <time_frame>21 days</time_frame>
    <description>to evlauate the symptom of adverse effect and the number of participates with adverse effect</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>safty test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLP,dose escalation,MTD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLP,dose escalation,MTD</intervention_name>
    <description>dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle</description>
    <arm_group_label>safty test</arm_group_label>
    <other_name>Fluorapacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged from 18 to 70 years old, male or female;&#xD;
&#xD;
          -  histologically or cytologically proven advanced malignant solid tumors;&#xD;
&#xD;
          -  cancer patients after conventional treatment failure and lack of effective treatment,&#xD;
             or patients refusing effective treatment of existing practices;&#xD;
&#xD;
          -  patients receiving the last treatment (chemotherapy, radiotherapy, biological therapy,&#xD;
             targeted therapy, or other study drugs) for at least 4 weeks;&#xD;
&#xD;
          -  expected survival time&gt;3 months;&#xD;
&#xD;
          -  ECOG score 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  viral activity in patients&#xD;
&#xD;
          -  allergic to drugs or excipients;&#xD;
&#xD;
          -  hypersensitivity to paclitaxel injection patients;&#xD;
&#xD;
          -  HIV antibody positive, or suffering from other acquired and congenital immune&#xD;
             deficiency disease, or history of organ transplantation;&#xD;
&#xD;
          -  neutrophil count &lt;1.5 × 109 / L, platelets &lt;100 × 109 / L, or hemoglobin &lt;90g / L;&#xD;
&#xD;
          -  normal serum creatinine higher than 1.5 times the upper limit of reference range or&#xD;
             the muscle of liver clearance &lt;60ml/min;&#xD;
&#xD;
          -  no case of liver ALT or AST&gt; 2.5 times the upper limit of normal, or liver metastases&#xD;
             than normal under the ALT or AST 5 times upper limit of reference range;&#xD;
&#xD;
          -  fever or body temperature above 38 ℃ can be clinically significant impact on clinical&#xD;
             trials of active infection;&#xD;
&#xD;
          -  medications failed to control hypertension (systolic pressure is over 160 mmHg or&#xD;
             diastolic pressure over 100mmHg);&#xD;
&#xD;
          -  significant cardiovascular abnormalities (such as myocardial infarction, superior vena&#xD;
             cava syndrome), or clinically significant arrhythmias (such as long QT syndrome,&#xD;
             Corrected QTc not be measured or ≧ 480 ms);&#xD;
&#xD;
          -  calcium, potassium, magnesium ions below the lower limit of normal;&#xD;
&#xD;
          -  &gt; I-level peripheral neuropathy&#xD;
&#xD;
          -  Prior to the toxicity of anticancer therapy has not been restored or not from the&#xD;
             surgery before full recovery;&#xD;
&#xD;
          -  bone metastases for the primary lesion of palliative radiotherapy;&#xD;
&#xD;
          -  any clinical problems can not control (such as the serious mental, neurological,&#xD;
             cardiovascular, respiratory and other diseases);&#xD;
&#xD;
          -  a tumor metastasis, or a variety of mental disorders center; no history of asthma;&#xD;
&#xD;
          -  pregnancy or breast-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianying zhou, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>nong xu, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>jianzhong shentu, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jianzhong shentu, doctor</last_name>
    <phone>+86-571-87236560</phone>
    <email>stjzcn@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lihua wu, doctor</last_name>
    <phone>+86-571-87236560</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GCP center,First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianzhong shentu, professor</last_name>
      <phone>+86-571-87236560</phone>
      <email>stjzcn@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>qiong zhao, professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>weijia fang, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wanhong Xu,Deputy General Manager</name_title>
    <organization>Acea Bio (Hangzhou) Co., Ltd.</organization>
  </responsible_party>
  <keyword>dose escalation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

